Avaliação do efeito da quercetina em ratos Wistar com Síndrome Metabólica
DOI:
https://doi.org/10.34019/1982-8047.2018.v44.16955Palavras-chave:
Síndrome metabólica, Obesidade, QuercetinaResumo
Introdução: O tratamento da síndrome metabólica (SM) é um desafio, uma vez que terapias não medicamentosas são de difícil implementação e o tratamento farmacológico ideal não está totalmente estabelecido. Objetivo: Avaliar o efeito da quercetina na pressão arterial (PA), dislipidemia e acúmulo de gordura visceral em modelo experimental de SM induzida por dieta hiperlipídica. Métodos: Ratos Wistar receberam ração hiperlipídica a partir da quarta semana de vida, por 20 semanas. O grupo tratado recebeu quercetina a partir da oitava semana de vida. Avaliou-se semanalmente o peso corporal e a PA de cauda por pletismografia. Ao final do experimento foram realizados testes de perfil glicêmico e lipídico. Resultados: A administração de dieta hiperlipídica se associou ao desenvolvimento de SM, caracterizada por acúmulo central de gordura, hipertensão arterial, hiperglicemia e hipertrigliceridemia. A quercetina não apresentou eficácia no tratamento das comorbidades que compõem a SM. Conclusão: A administração crônica diária da quercetina em modelo experimental de SM induzida por dieta hiperlipídica não alterou de forma significante o perfil nutricional, metabólico e pressórico dos animais.
Downloads
Referências
Grundy M, Brewer Jr. HB, Cleeman JI, Smith SC Jr, Lenfant C. Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific c Issues Related to Defination of Metabolic Syndrome. Circulation 2004;109:433-8
Simmons RK, Alberti KGMM, Gale EAM et al. "The metabolic syndrome: useful concept or clinical tool? Report of a WHO expert consultation". Diabetologia 2010;53:600-5.
FORD, E. S.; GILES, W. H.; DIETZ, W H. Prevalence of the metabolic syndrome among US adults; findings from the Third National Health and Nutrition Examination Survey. The Journal of American Medical Association, v. 287, n. 3, p. 356 – 359, 2002.
DORO, A. R. et al. Analysis on the association of physical activity with metabolic syndrome in a population-based study of Japanese-Brazilians. Arquivos Brasileiros de Endocrinologia e Metabologia, v. 50, n. 6, p. 1066-1074, 2006.
SALAROLI, L. B. et al. Prevalence of metabolic syndrome in population based study, Vitória, ES-Brazil. Arquivos Brasileiros de Endocrinologia e Metabologia,v. 51, n. 7, p. 1143-1152, 2007.
Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010;56:1113-32.
Ogden CL, Carrol MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
Global health risks: mortality and burden of disease attributable to selected major risks. Geneva, World Health Organization, 2009 (http://www.who.int/healthinfo/global_burden_disease/GlobalHealthRisks_report_full.pdf).
Perez-Vizcaino F, Duarte J. Flavonols and cardiovascular disease. Molecular Aspects of Medicine. 2010; 31: 478–94.
Birt DF, Hendrich S, Wang W. Dietary agents in cancer prevention: flavonóides and isoflavonoids. Pharmacology & Therapeutics. 2001; 90: 157-77.
Mackraj I, Govender T, Ramesar S. The antihypertensive effects of quercetin in a salt sensitive model of hypertension. J Cardiovasc Pharmacol. 2008; 51: 239–45.
Duarte J, Galisteo M, Ocete MA, Pérez-Vizcaino F, Zarzuelo A, Tamargo J. Effects of chronic quercetin treatment on hepatic oxidative status of spontaneously hypertensive rats. Mol Cell Biochem. 2001; 221: 155–160.
Edwards RL, Lyon T, Litwin SE, Rabovsky A, Symons JD, Jalili T Quercetin reduces blood pressure in hypertensive subjects. J Nutr. 2007; 137: 2405–11.
Shen C, Zhu Z, Yan Z, Ni Y. P-513: High fat plus high salt diet induced metabolic syndrome in wistar rat. Am J Hypertens 2004;17:220-35.
Toshiharu A, Issei T, Hisashi S, Nobuaki W, Makoto O. High-fat hypercaloric diet induces obesity, glucose intolerance and hyperlipidemia in normal adult male Wistar rat. Diabetes Res Clin Pract 1996;31:27-35.
Nascimento AF, Sugizaki MM, Leopoldo AS, Lima-Leopoldo AP, Nogueira CR, Novelli EL, Padovani CR, Cicogna AC. Misclassification probability as obese or lean in hypercaloric and normocaloric diet. 2008; 41(3):253-9.
Dourmashkin JT, Chang GQ, Gayles EC et al. Different forms of obesity as a function of diet composition. Int J Obes 2005;29:1368-78.
Machado H, Guerra MO, Peters V. Implantação e padronização da técnica de aferição indireta da pressão arterial em ratos Wistar da colônia do biotério do Centro de Biologia da Reprodução (CBR). RIEE 2010;2:60-1.
Raji IA, Mugabo P, Obikeze K. Effect of Tulbaghia violacea on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats. J Ethnopharmacol 2011. [Epub ahead of print].
Marchionne EM, Diamond-Stanic MK, Prasonnarong M, Henriksen EJ. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol 2012;302:137-42.
Yamabe N, Kang KS, Goto E, Tanaka T, Yokozawa T. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in Streptozotocin-treated diabetic rats. Biol Pharm Bull 2007;30:520-6.
Zheng S, Noonan WT, Metreveli NS et al. Development of late stage diabetic nephropathy in OVE26 diabetic mice. Diabetes 2004;53:3248-57.
Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and the prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes Care 2003;52:1210-4.
Sarah Egert, Anja Bosy-Westphal, Jasmin Seiberl, Claudia Kurbitz, Uta Settler, Sandra Plachta-Danielzik, Anika E. Wagner, Jan Frank, Jurgen Schrezenmeir, Gerald Rimbach, Siegfried Wolffram and Manfred J. Muller. Quercetin reduces systolic blood pressure and plasma oxidized low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. British Journal of Nutrition (2009), 102, 1065–1074
Laura K. Stewart, Jeff L. Soileau, David Ribnicky, Zhong Q. Wang, Ilya Raskin, Alexander Poulev, Martin Majewski, William T. Cefalu, Thomas W. Gettys. Quercetin transiently increases energy expenditure but persistently decreases circulating markers of inflammation in C57BL/6J mice fed a high-fat diet. Metabolism Clinical and Experimental 57 (Suppl 1) (2008) S39–S46
Uemura K, Mori NT. Nagoya J. Influence of age and sex on high-fat diet-induced increase in blood pressure. Med Sci. 2006; 68: 109 –14.
Hall JE. Pathophysiology of obesity hypertension. Curr Hypertens Rep 2000;2: 139-47.
Rivera l, Morón R, Sánchez M, Zarzuelo A, Galisteo M. Quercetin Ameliorates Metabolic Syndrome and Improves the Inflammatory Status in Obese Zucker Rats. Obesity 2008; 16: 2081–2087
Jalili T, Carlstrom J, Kim S, Freeman D, Jin H, Wu TC, Litwin SE, Symons JD. Quercetin-supplemented diets lower blood pressure and attenuate cardiac hypertrophy in rats with aortic constriction. J Cardiovasc Pharmacol 2006; 47: 531–41.
Aguila Mb, Mandarim-De-Lacerda Ca. Effects of chronic high fat diets on renal function and cortical structure in rats. Exp Toxic Pathol 2003;55:187-95.
De Paula RB, Silva AA, Hall JE. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 2004;43:1-7.
Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol 2011;2011:1-14.
Downloads
Publicado
Como Citar
Edição
Seção
Licença
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
